WallStSmart
SNSE

Sensei Biotherapeutics Inc

NASDAQ: SNSE · HEALTHCARE · BIOTECHNOLOGY

$20.73
+4.76% today

Updated 2026-06-04

Market cap
$15.31M
P/E ratio
P/S ratio
EPS (TTM)
$-142.72
Dividend yield
52W range
$6 – $37
Volume
0.0M

Sensei Biotherapeutics Inc (SNSE) Financial statements

SEC filings — annual and quarterly data.

Balance sheet — annual

Item20182019202020212022202320242025
Total assets$1.85M$1.22M$21.43M$153.22M$118.38M$74.37M$45.36M$22.90M
Cash & equivalents$653000.00$251000.00$16.60M$7.16M$17.80M$13.01M$9.99M$8.67M
Current assets$1.28M$502000.00$20.08M$148.54M$108.59M$67.25M$41.93M$21.51M
Total liabilities$55.33M$69.88M$5.54M$6.71M$14.97M$9.48M$6.97M$4.31M
Current liabilities$2.66M$21.71M$4.83M$4.89M$9.07M$5.64M$5.45M$4.25M
Long-term debt$4.05M$567000.00
Shareholder equity$-53.48M$-68.66M$15.89M$146.51M$103.41M$64.89M$38.39M$18.59M
Retained earnings$-75.57M$-92.31M$-112.41M$-149.21M$-197.79M$-231.90M$-262.05M$-283.14M
Accounts receivable
Inventory
Goodwill

Frequently asked questions

How much free cash flow does SNSE generate?

SNSE produced $-20.47M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.

Is SNSE's balance sheet healthy?

SNSE holds $8.67M in cash and equivalents against — in long-term debt, on $18.59M of shareholder equity. That debt is best read against the cash flow the business throws off each year.